7200AA21RFA00008: The Microbicide 2021 Introduction and Access Project
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Agency for International Development notices from 2021.
Agency for International Development offered grants of up to $85.0 million (at least $1) to any type of organization. It expected to make one award. Applications closed on March 28, 2021.
From the official notice on Grants.gov, last changed January 27, 2021. Checked November 7, 2026.
- Award ceiling$85.0 million
- Award floor$1
- Expected awards1
- Cost sharingRequired
- Funding typeCooperative Agreement
Key dates
| Posted | January 27, 2021 |
|---|---|
| Deadline | March 28, 2021 |
| Archived by Grants.gov | April 27, 2021 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Past USAID Foreign Assistance for Programs Overseas awards averaged $8.7 million; this notice allows up to $85.0 million per award.
- Most of the program's money (54% over five years) went to nonprofits.
- The notice requires cost sharing or matching funds, so you must contribute part of the project cost.
What the grant funds
USAID’s Microbicide Program aims to bridge gaps and reduce barriers among R&D, regulatory approval, introduction, access, and scale-up of close-to-market products through program research and country engagement activities that identify and address obstacles, gaps, and bottlenecks that delay timely access to new prevention technologies and their resulting impact.
Who has won USAID Foreign Assistance for Programs Overseas grants before
From fiscal 2021 to 2025, USAID Foreign Assistance for Programs Overseas (98.001) awarded $37 billion across 4,233 grant awards, an average of $8.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Miscellaneous Foreign Awardees | District of Columbia | 489 | $6.9 billion |
| Family Health International | North Carolina | 91 | $2.1 billion |
| Catholic Relief Services - United States Conference of Catholic Bishops | Maryland | 128 | $1.2 billion |
| Save the Children Federation, Inc. | Connecticut | 100 | $814 million |
| Research Triangle Institute | North Carolina | 33 | $756 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is 7200AA21RFA00008 still open?
No. It closed on March 28, 2021.
Who can apply for The Microbicide 2021 Introduction and Access Project?
Agency for International Development accepted applications from any type of organization.
What is the deadline for The Microbicide 2021 Introduction and Access Project?
Closed March 28, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $85.0 million each.
Who has won USAID Foreign Assistance for Programs Overseas grants before?
The largest recipients over five fiscal years were Miscellaneous Foreign Awardees, Family Health International, Catholic Relief Services - United States Conference of Catholic Bishops. The program made 4,233 awards worth $37 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)